SATB2 and neoplasm: Compared to SATB2-high neoplasms, SATB2-low/absent CRCs were significantly increased in CRCs with high (Bd3) tumour budding activity and in poorly differentiated carcinomas according to the WHO grade (p < 0.001, respectively).